- Teleflex (NYSE:TFX) agrees to acquire privately held NeoTract for up to $1.1B. Pleasanton, CA-based NeoTract develops devices used in urology. It currently commercializes one product, the UroLift System, designed to hold the a man's enlarged prostate tissue out of the way so that it no longer blocks the urethra.
- UroLift was CE Mark'd in 2010 and received de novo 510(k) clearance in the U.S. in 2013.
- Under the terms of the agreement, Teleflex will pay $725M upfront and up to $375M in commercial milestones through 2020. The deal should close within 30 days.